CN111686202A - Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof - Google Patents
Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof Download PDFInfo
- Publication number
- CN111686202A CN111686202A CN202010546659.2A CN202010546659A CN111686202A CN 111686202 A CN111686202 A CN 111686202A CN 202010546659 A CN202010546659 A CN 202010546659A CN 111686202 A CN111686202 A CN 111686202A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- ulcerative colitis
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound traditional Chinese medicine composition for inhibiting the inflammatory progress of active ulcerative colitis, which comprises the following components in parts by weight: 10-15 parts of Chinese pulsatilla root, 8-15 parts of Sichuan phellodendron bark, 3-8 parts of raw rhubarb, 10-20 parts of dahurian patrinia herb, 15-30 parts of hairyvein agrimony, 10-20 parts of carbonized sanguisorba root, 10-20 parts of stewed costus root, 6-15 parts of bletilla, 10-20 parts of pseudo-ginseng, 3-8 parts of dragon's blood and 5-10 parts of raw licorice; the invention also discloses a preparation method of the compound traditional Chinese medicine composition and application of the compound traditional Chinese medicine composition in preparing medicines for treating ulcerative colitis. The invention has the advantages of high use safety, obvious curative effect, low side effect, low treatment cost and high patient compliance, and can also increase the curative effect by matching with western medicines.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and in particular relates to a compound traditional Chinese medicine composition for inhibiting the inflammatory progress of active ulcerative colitis as well as a preparation method and application thereof.
Background
Ulcerative colitis has now become a globally refractory disease. It is speculated that by 2025, chinese ulcerative colitis patients will exceed 100 ten thousand, at which time a huge burden will be placed on social public health. The ulcerative colitis is not long lasting and canceration is easy to occur. Therefore, early control of inflammation is an effective way to prevent UC canceration.
The therapeutic drugs for ulcerative colitis relate to aminosalicylic acid preparations, glucocorticoids, immunosuppressive agents and biological agents, but although a great number of new therapeutic drugs are developed in recent years, only 45% of patients can achieve the effects of temporary induction and sustained relief, and the drugs have obvious toxic and side effects and high price, and some patients can also have drug resistance. Therefore, there is an urgent need to search for new therapeutic approaches.
The combined treatment of traditional Chinese medicine and western medicine is a development direction of the treatment of ulcerative colitis. The traditional Chinese medicine considers that the ulcerative colitis is mainly caused by spleen deficiency, the deficiency of vital qi is easily damaged by exogenous pathogenic factors and food consumption, the emotion is coherent, the spleen fails to transport and transport, the damp pathogen grows internally, the heat is transformed for a long time, the qi of the fu organs is blocked, the qi and blood are stagnated, the blood and fat are damaged, the pus and the blood are formed, and the paralysis gradually becomes red and white in diarrhea. The main pathogenesis is the disorder of qi, blood, yin and yang of the zang-fu organs, which is usually caused by dysfunction of the spleen in transportation and bowel movement, or dysfunction of the wood in restraining earth and kidney deficiency, malnutrition of the middle-jiao and earth in transportation and transformation. The spleen deficiency is the root of the pathogenesis, and is also related to the liver and kidney, and the pathological properties are marked by the deficiency of the principal and excess of the principal. In the active stage, UC is mainly marked by excess and has the main pathological factors of damp-heat and blood stasis, and the UC is used for clearing and resolving damp-heat, promoting blood circulation and removing blood stasis. The Chinese traditional medicine and Chinese and western medicine combined therapy has specific advantages for improving curative effect, relieving symptoms and avoiding relapse, and has the characteristics of individuation and multiple targets. Therefore, the invention is urgently needed to invent a traditional Chinese medicine which has high use safety, obvious curative effect, low side effect, low treatment cost and high patient compliance and can increase the curative effect by matching with western medicines.
Disclosure of Invention
The invention aims to solve the technical problem of providing a compound traditional Chinese medicine composition for inhibiting the progression of active ulcerative colitis, which has high use safety, obvious curative effect, low side effect, low treatment cost and high patient compliance and can increase the curative effect by matching with western medicines.
The technical problem to be solved by the invention is to provide a preparation method of the compound traditional Chinese medicine composition.
The invention finally aims to solve the technical problem of providing the application of the compound traditional Chinese medicine composition.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
a compound traditional Chinese medicine composition for inhibiting the inflammatory progress of active ulcerative colitis is prepared from the following raw material medicines in parts by weight: 10-20 parts of Chinese pulsatilla root, 8-20 parts of Sichuan phellodendron bark, 3-8 parts of raw rhubarb, 10-30 parts of dahurian patrinia herb, 15-30 parts of hairyvein agrimony, 10-20 parts of carbonized sanguisorba root, 10-20 parts of stewed costus root, 6-15 parts of bletilla, 10-20 parts of pseudo-ginseng, 3-10 parts of dragon's blood and 5-10 parts of raw licorice.
Further, the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis is characterized in that: the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 10-15 parts of Chinese pulsatilla root, 8-15 parts of Sichuan phellodendron bark, 3-8 parts of raw rhubarb, 10-20 parts of dahurian patrinia herb, 15-30 parts of hairyvein agrimony, 10-20 parts of carbonized sanguisorba root, 10-20 parts of stewed costus root, 6-15 parts of bletilla, 10-20 parts of pseudo-ginseng, 3-8 parts of dragon's blood and 5-10 parts of raw licorice.
Further, the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis is characterized in that: the compound Chinese medicinal composition is in the form of decoction, syrup, mixture, granule, tablet or capsule.
A preparation method of a compound traditional Chinese medicine composition for inhibiting the inflammatory progress of active ulcerative colitis comprises the following steps: decocting Chinese medicinal materials of radix Pulsatillae, cortex Phellodendri, radix et rhizoma Rhei, herba Patriniae, herba et Gemma Agrimoniae, charred radix Sangusorbae, radix aucklandiae preparata, rhizoma Bletillae, Notoginseng radix, and Glycyrrhrizae radix in water, and adding sanguis Draxonis.
Further, the preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis is as follows: in each decoction, the weight of the added water is 5-20 times of the total weight of the traditional Chinese medicinal materials; the decocting times are 1-3 times, and the decocting time is 1-3 hours each time.
Further, the preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis is as follows: adding water for decoction, and concentrating the decoction until the relative density is 1.05-1.15 to obtain a concentrated solution.
Further, the preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis is as follows: after water is added for decoction, the decoction is concentrated to the relative density of 1.05-1.15, ethanol is added until the ethanol content of the decoction reaches 60-90%, then the extraction is carried out, solid-liquid separation is carried out, the supernatant is taken, and the ethanol in the supernatant is recovered to the full extent to obtain the concentrated solution.
Further, the preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis is as follows: adding or not adding sucrose into the concentrated solution, sterilizing, and making into syrup or decoction; or adding dextrin and steviosin into the concentrated solution, and making into tablet, capsule or granule.
An application of a compound traditional Chinese medicine composition for inhibiting the inflammatory progress of active ulcerative colitis is disclosed, wherein: the compound traditional Chinese medicine composition is applied to the preparation of medicines for inhibiting active ulcerative colitis and medicines for inhibiting colon cancer liver metastasis or rectal cancer liver metastasis.
An application of a compound traditional Chinese medicine composition for inhibiting the inflammatory progress of active ulcerative colitis is disclosed, wherein: the compound traditional Chinese medicine composition and the mesalazine are used together to prepare the medicine for inhibiting the active ulcerative colitis.
Through the implementation of the technical scheme, the invention has the beneficial effects that: in the formula, the Chinese pulsatilla root is a good medicine for treating heat-toxin and bloody dysentery, is used as a monarch medicine for clearing heat and removing toxicity, and cooling blood and stopping dysentery; chuan Huang Bai is good at clearing damp-heat in lower energizer, and is complementary with Bai Tou Weng to strengthen the actions of Bai Tou Weng in clearing damp-heat in lower energizer; the raw rhubarb has cold nature and enters blood, and helps the Chinese pulsatilla root to cool blood and stop diarrhea, and the raw rhubarb and the Chinese pulsatilla root are used as ministerial medicines to play the roles of clearing heat, eliminating dampness and cooling blood; herba Patriniae, herba et Gemma Agrimoniae, and radix Sangusorbae for removing toxic substances, healing sore, and stopping bleeding; notoginseng radix and sanguis Draxonis enter blood system, and have effects in promoting blood circulation, relieving pain, removing blood stasis, stopping bleeding, and enhancing "hemostasis without blood stasis" by combining with rhizoma Bletillae; the seven medicines are used as adjuvant medicines to perform the effects of removing toxicity and dissolving stasis; the raw licorice root is used as a guiding drug and is used for harmonizing the effects of the other drugs in the prescription, clearing heat and eliminating dampness, promoting blood circulation by removing blood stasis, and cooling blood and stopping bleeding; for patients with active ulcerative colitis, the medicine can reduce inflammatory infiltration of ulcerative colitis, improve mucosa healing and improve the treatment efficiency; meanwhile, the medicine has low side effect, low treatment cost and high patient compliance, can increase the curative effect by matching with western medicines, and is easy to popularize and apply.
Detailed Description
The present invention will be further described with reference to the following specific examples. The invention will be better understood from the following examples. However, it is easily understood by those skilled in the art that the contents described in the embodiments are only for illustrating the present invention and should not be limited to the invention described in detail in the claims.
Example 1
A compound combination drug for inhibiting the inflammatory progress of active ulcerative colitis comprises the following components in parts by weight:
10 parts of Chinese pulsatilla root, 10 parts of golden cypress, 5 parts of raw rhubarb, 15 parts of dahurian patrinia herb, 15 parts of hairyvein agrimony, 10 parts of carbonized sanguisorba root, 10 parts of stewed costustoot, 10 parts of common bletilla pseudobulb, 10 parts of pseudo-ginseng, 5 parts of dragon's blood and 5 parts of raw liquorice, and 11 medicines are totally used.
Weighing the 11 traditional Chinese medicine decoction pieces according to the proportion of the prescription, adding water which is 10 times of the total weight of the raw material medicines, and decocting and extracting for 3 times, 1 hour each time. Mixing decoctions to obtain decoction.
Concentrating the decoction to relative density of 1.10 (measured at 60 deg.C), adding ethanol until ethanol content reaches 60%, and standing for more than 12 hr. The supernatant was filtered, ethanol was recovered to completion, and the filtrate was concentrated to a relative density of about 1.10 (measured at 60 ℃). Adding simple syrup, adding distilled water to 1g per mL decoction pieces, filtering, packaging, and sterilizing to obtain compound medicinal syrup.
Example 2
A medicine for inhibiting the inflammatory progression of active ulcerative colitis comprises the following components in parts by weight:
10 parts of Chinese pulsatilla root, 10 parts of golden cypress, 5 parts of raw rhubarb, 20 parts of dahurian patrinia herb, 15 parts of hairyvein agrimony, 15 parts of carbonized sanguisorba root, 10 parts of stewed costustoot, 10 parts of common bletilla pseudobulb, 10 parts of pseudo-ginseng, 5 parts of dragon's blood and 5 parts of raw liquorice, and 11 medicines are totally used. Weighing the 11 traditional Chinese medicine decoction pieces according to the proportion of the prescription, adding water which is 20 times of the total weight of the raw material medicines, and decocting and extracting for 3 times, 1 hour each time. Mixing decoctions, concentrating to relative density of 1.08 (measured at 60 deg.C), adding ethanol until ethanol content reaches 60%, standing for more than 24 hr, filtering to obtain supernatant, recovering ethanol, and concentrating to relative density of 1.08 (measured at 60 deg.C). Adding distilled water to each mL to obtain decoction pieces 1g, mixing, filtering, packaging, and sterilizing to obtain compound medicinal mixture.
Example 3
A compound combination drug for inhibiting the inflammatory progress of active ulcerative colitis comprises the following components in parts by weight:
10 parts of Chinese pulsatilla root, 10 parts of golden cypress, 5 parts of raw rhubarb, 10 parts of dahurian patrinia herb, 15 parts of hairyvein agrimony, 15 parts of carbonized sanguisorba root, 10 parts of stewed costustoot, 10 parts of common bletilla pseudobulb, 10 parts of pseudo-ginseng, 5 parts of dragon's blood and 5 parts of raw liquorice, and 11 medicines are totally used.
Weighing the 11 traditional Chinese medicine decoction pieces according to the proportion of the prescription, adding water with the amount of 5 times of the total weight of the raw material medicines, and decocting and extracting for 3 times, 1 hour each time. Mixing decoctions, concentrating to relative density of 1.10 (measured at 60 deg.C), adding ethanol until ethanol content reaches 60%, standing for more than 24 hr, filtering to obtain supernatant, recovering ethanol, and concentrating to relative density of 1.33 (measured at 60 deg.C). Adding appropriate amount of dextrin and stevioside, granulating, drying, grading, and packaging to obtain compound medicinal granule.
Example 4
A compound combination drug for inhibiting the inflammatory progress of active ulcerative colitis comprises the following components in parts by weight:
10 parts of Chinese pulsatilla root, 10 parts of golden cypress, 5 parts of raw rhubarb, 15 parts of dahurian patrinia herb, 20 parts of hairyvein agrimony, 15 parts of carbonized sanguisorba root, 10 parts of stewed costustoot, 10 parts of common bletilla pseudobulb, 10 parts of pseudo-ginseng, 5 parts of dragon's blood and 5 parts of raw liquorice, and 11 medicines are totally used. Weighing the 11 traditional Chinese medicine decoction pieces according to the proportion of the prescription, adding water which is 10 times of the total weight of the raw material medicines, and decocting and extracting for 3 times, 1 hour each time. Mixing decoctions, concentrating to relative density of 1.09 (measured at 60 deg.C), adding ethanol until ethanol content reaches 60%, standing for more than 24 hr, filtering to obtain supernatant, recovering ethanol, and concentrating to relative density of 1.35 (measured at 60 deg.C). Adding appropriate amount of starch, granulating, drying, grading, tabletting, coating, and packaging to obtain compound medicinal tablet.
Example 5
A compound combination drug for inhibiting the inflammatory progress of active ulcerative colitis comprises the following components in parts by weight:
10 parts of Chinese pulsatilla root, 10 parts of golden cypress, 5 parts of raw rhubarb, 10 parts of dahurian patrinia herb, 15 parts of hairyvein agrimony, 15 parts of carbonized sanguisorba root, 10 parts of stewed costustoot, 10 parts of common bletilla pseudobulb, 10 parts of pseudo-ginseng, 5 parts of dragon's blood and 5 parts of raw liquorice, and 11 medicines are totally used. Weighing the 11 traditional Chinese medicine decoction pieces according to the proportion of the prescription, adding water which is 10 times of the total weight of the raw material medicines, and decocting and extracting for 2 times, 1 hour each time. Mixing decoctions, concentrating to relative density of 1.12 (measured at 60 deg.C), adding ethanol until ethanol content reaches 60%, standing for more than 24 hr, filtering to obtain supernatant, recovering ethanol, and concentrating to relative density of 1.32 (measured at 60 deg.C). Adding appropriate amount of starch, granulating, drying, grading, making into capsule, and packaging to obtain compound medicinal capsule.
The clinical research of the traditional Chinese medicine compound for inhibiting the active ulcerative colitis comprises the following steps: optionally, the prescription of the compound medicine prepared in the above examples 1-5 is prepared into decoction for clinical and animal experiments of the compound medicine.
Example 6
Taking the formula of the typical embodiment 1 as an example, the effect of other embodiments is equivalent, and the following concrete effects are achieved:
study subjects: 60 patients with active ulcerative colitis with excessive heat and blood stasis are treated by outpatient service and hospitalization of affiliated Zhang harbor hospital of Nanjing Chinese medicine university from 10 months to 12 months in 2018.
Study of drugs: a decoction was prepared as prescribed in example 1.
The research method comprises the following steps: the 60 patients in the group were randomly divided into treatment groups and control groups. The treatment group is treated by the bowel clearing decoction and the mesalazine, and the control group is treated by the mesalazine, wherein the treatment course is 3 months. Mayo score, traditional Chinese medicine clinical symptom score and Mayo endoscope sub-score before and after treatment of two groups of patients are respectively observed, an IBDQ scale is adopted to carry out life quality score, the expression of TRAF6 and p65 of mucosal tissues under an enteroscope is measured by immunohistochemistry, and the expression of TLR4 is observed by immunofluorescence. Statistical analysis is carried out by using SPSS24.0, the differences of the total effective rate of patients before and after treatment, the traditional Chinese medicine symptom integral, the Mayo score, the Mayo endoscope sub-score, the mucous membrane healing rate and the life quality integral are compared, the expression change of the colon tissue TLR4 is analyzed by immunofluorescence staining, and the expression change of the colon tissue TRAF6 and p65 is analyzed by immunohistochemistry.
The research results are as follows: and (3) comparing the comprehensive curative effects of the diseases: the curative effect of the treatment group is better than that of the control group. The total effective rate of the treatment group is 93.33%, the control group is 73.33%, the treatment group is higher than the control group, and the difference has statistical significance (P) by chi fang test<0.05). The traditional Chinese medicine syndrome curative effect comparison: the integral and total integral of the Chinese medicine symptoms (diarrhea, mucopurulent bloody stool, abdominal pain and tenesmus) before treatment of the two groups of patients have no statistical difference (P) through t test>0.05), the integral and the total integral of the symptoms of the Chinese traditional medicine in the two groups are reduced after treatment, and the statistical significance is shown by t test (P)<0.05), but the treatment group was more significant in improving diarrhea, and the difference was statistically significant (△P<0.05); has better curative effect on improving mucopurulent bloody stool, abdominal pain, tenesmus and total integral, and the difference has statistical significance (*P<0.01). Comparison of Mayo scores: the Mayo scores of the two groups of patients before treatment were not statistically different by t-test (P)>0.05), both groups had a decrease in Mayo score after treatment, and were statistically significant by t-test (P)<0.05). However, the treatment groups were more significant in improving the Mayo score, and the differences were statistically significant (P)<0.01). And (3) comparing the scores of intestinal mucosa lesions of two groups of patients under endoscope: the Mayo endoscope sub-scores of intestinal mucosa before treatment of two groups of patients have no statistical difference through t test (P)>0.05), the Mayo endoscope sub-score of the intestinal mucosa of the two groups after treatment is reduced compared with that before treatment, and the difference has statistical significance (P is less than 0.05), but the intestinal mucosa of the treatment group is improved more obviously, and the difference has statistical significance (P is less than 0.01). Endoscopic mucosal healing rates for treatment of two groups of patients were compared: the healing rate of the mucous membrane of the treatment group is 86.67 percent, and the healing rate of the mucous membrane of the control group is 53 percent33%, the treated group was higher than the control group, and the differences were statistically significant (P) by chi-square test<0.01). The quality of life of two groups of patients was compared: the IBDQ score and total score of 4 before treatment in both groups of patients were not statistically different by t-test (P)>0.05), the IBDQ score and the total score of 4 dimensionalities of the two groups of patients after treatment are reduced compared with those before treatment, and the difference is statistically significant (P is less than 0.05), but the treatment groups are more obviously improved in each dimensionality and the total score, and the difference is statistically significant (P is less than 0.01). Immunohistochemistry of the colonic mucosa was compared in two groups of patients: no significant statistical difference was observed between TRAF6 and P65 expression in the first two groups of patients (P)>0.05). After treatment, the expression of TRAF6 and P65 in two groups of patients is reduced compared with that before treatment, and the difference has statistical significance (P is less than 0.05), but the improvement condition of the treatment group to TRAF6 and P65 is more obvious, and the difference has statistical significance (P is less than 0.01). Comparison of the reduced colonic mucosal immunohistochemistry TRAF6, p65 expression constitutive ratios in two groups of patients: the TRAF6 attenuation composition ratio was 90% in the treated group and 66.67% in the control group, and the difference was statistically significant (P < 0.05) in the two groups. The reduction in P65 for the treatment group consisted of 93.33% compared to 63.33% for the control group, with a statistical significance of the difference (P < 0.01). Colon mucosal immunofluorescence of two groups of patients compared TLR4 expression changes: TLR4 expression is obvious in two groups of patients before treatment. After treatment, the expression of the treated group was generally lower than that of the control group.
From the clinical tests, the intestine clearing decoction has obvious synergistic effect on patients with ulcerative colitis.
Example 7
Taking the formula of the typical embodiment 1 as an example, the effect of other embodiments is equivalent, and the following concrete effects are achieved:
experimental animals: 40 male C57BL/6 mice, weighing 18-23 g, purchased from the research center for New drugs in Showa Soviet, and having a certification number: 201915038
Experimental drugs: the decoction prescribed in example 1 was prepared and concentrated to a concentration equivalent to 4.4g/mL of crude drug.
Mesalazine enteric-coated granules: specification 0.5 g/bag, purchased from pharmaceutical company ltd, shanghai love, lot number: 140241. preparing mother liquor with mass concentration of 40mg/ml according to the proportion of 200 mg/kg.
Grouping experiments: 40 male C57BL/6 mice were randomly divided into 4 groups, a normal control group, a model group, a 5-ASA group, and a bowel clearing decoction group, each of which contained 10 mice.
Building a UC mouse model: except for the normal control group, the mice in the other groups were freely drinking 2.5% DSS solution for 5 days, and then replaced with normal drinking water. And (4) evaluating whether the model building is successful according to the general condition, weight change, DAI score and the like of the mouse.
The administration scheme is as follows: the 5-ASA group is administered with 200mg/kg 5-ASA solution per day for intragastric administration; the intestine clearing decoction group is administered with 44g/kg stomach; the normal control group and the model group were administered distilled water for intragastric administration. Gavage was performed 1 time per day for 10 days. The mice were sacrificed on the last day, blood was taken from the inner canthus of the eye, and colon tissue and spleen were extracted. The specific pharmaceutical composition and administration mode are shown in table 1.
TABLE 1 pharmaceutical composition and mode of administration
The experimental results are as follows:
1) general conditions are as follows: after administration, the mice were observed daily for mental, activity, diet, feces, etc. and no abnormality was found.
2) The weight change of mice in each group is reduced when the treatment is finished, the weight average of mice in the model group, the positive control group and the traditional Chinese medicine treatment group is reduced to some extent, the reduction degree of the traditional Chinese medicine compound group is the lowest, the difference is obvious compared with the model group, P is less than 0.05, and the specific comparison is shown in table 2.
Table 2 effect of each drug treatment group on mouse body weight
| Group of | Before administration (g) | After administration (g) |
| Normal group | 24.0±0.83 | 25.27±1.02 |
| Model set | 24.68±1.21 | 18.07±1.13 |
| Positive control group) | 23.97±0.56 | 19.41±0.89 |
| Traditional Chinese medicine compound group | 24.93±0.75 | 20.56±1.11 |
3) The influence of the traditional Chinese medicine compound on the length of the colon: at the end of treatment, the colon length of the mice in the model group, the positive control group and the traditional Chinese medicine treatment group is shortened compared with that in the normal group, while the traditional Chinese medicine compound group is shortened to the lowest extent, and has obvious difference compared with the model group, P is less than 0.05, and the specific comparison is shown in Table 3.
TABLE 3 Effect of each drug treatment group on Colon Length in mice
| Group of | Length of colon |
| Normal group | 8.79±1.01 |
| Model set | 6.28±0.39 |
| Positive control group | 6.91±0.50 |
| Traditional Chinese medicine compound group | 7.60±1.12 |
4) Effect of the herbal compound on DAI scores after administration to mice of each group: when the treatment is finished, the DAI scores of the mice in the model group, the positive control group and the traditional Chinese medicine treatment group are all increased, while the increase degree of the traditional Chinese medicine compound group is minimum, the difference is obvious compared with the model group, P is less than 0.05, and the specific comparison is shown in Table 4.
TABLE 4 Effect of each drug treatment group on post-dose DAI scores
| Group of | DAI score |
| Normal group | 0 |
| Model set | 1.78±1.09 |
| Positive control group | 0.88±1.09 |
| Traditional Chinese medicine compound group | 0.57±0.79 |
The experiments show that the traditional Chinese medicine compound has obvious anti-inflammatory effect on ulcerative colitis model mice, and embodies the unique effect of the traditional Chinese medicine compound.
Clinical tests and animal experiments show that the traditional Chinese medicine compound has an obvious anti-inflammatory effect on active ulcerative colitis, and the unique effect of the traditional Chinese medicine compound is reflected.
In conclusion, the invention has the advantages that: in the formula, the Chinese pulsatilla root is a good medicine for treating heat-toxin and bloody dysentery, is used as a monarch medicine for clearing heat and removing toxicity, and cooling blood and stopping dysentery; chuan Huang Bai is good at clearing damp-heat in lower energizer, and is complementary with Bai Tou Weng to strengthen the actions of Bai Tou Weng in clearing damp-heat in lower energizer; the raw rhubarb has cold nature and enters blood, and helps the Chinese pulsatilla root to cool blood and stop diarrhea, and the raw rhubarb and the Chinese pulsatilla root are used as ministerial medicines to play the roles of clearing heat, eliminating dampness and cooling blood; herba Patriniae, herba et Gemma Agrimoniae, and radix Sangusorbae for removing toxic substances, healing sore, and stopping bleeding; notoginseng radix and sanguis Draxonis enter blood system, and have effects in promoting blood circulation, relieving pain, removing blood stasis, stopping bleeding, and enhancing "hemostasis without blood stasis" by combining with rhizoma Bletillae; the seven medicines are used as adjuvant medicines to perform the effects of removing toxicity and dissolving stasis; the raw licorice root is used as a guiding drug and is used for harmonizing the effects of the other drugs in the prescription, clearing heat and eliminating dampness, promoting blood circulation by removing blood stasis, and cooling blood and stopping bleeding; for patients with active ulcerative colitis, the medicine can reduce inflammatory infiltration of ulcerative colitis, improve mucosa healing and improve the treatment efficiency; meanwhile, the medicine has low side effect, low treatment cost and high patient compliance, can increase the curative effect by matching with western medicines, and is easy to popularize and apply.
Claims (10)
1. A compound traditional Chinese medicine composition for inhibiting the inflammatory progress of active ulcerative colitis is characterized in that: the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 10-20 parts of Chinese pulsatilla root, 8-20 parts of Sichuan phellodendron bark, 3-8 parts of raw rhubarb, 10-30 parts of dahurian patrinia herb, 15-30 parts of hairyvein agrimony, 10-20 parts of carbonized sanguisorba root, 10-20 parts of stewed costus root, 6-15 parts of bletilla, 10-20 parts of pseudo-ginseng, 3-10 parts of dragon's blood and 5-10 parts of raw licorice.
2. The compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis according to claim 1, wherein the compound traditional Chinese medicine composition comprises the following components: the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 10-15 parts of Chinese pulsatilla root, 8-15 parts of Sichuan phellodendron bark, 3-8 parts of raw rhubarb, 10-20 parts of dahurian patrinia herb, 15-30 parts of hairyvein agrimony, 10-20 parts of carbonized sanguisorba root, 10-20 parts of stewed costus root, 6-15 parts of bletilla, 10-20 parts of pseudo-ginseng, 3-8 parts of dragon's blood and 5-10 parts of raw licorice.
3. The compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis according to claim 1, wherein the compound traditional Chinese medicine composition comprises the following components: the compound Chinese medicinal composition is in the form of decoction, syrup, mixture, granule, tablet or capsule.
4. The preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis according to claim 1 or 2, characterized in that: decocting Chinese medicinal materials of radix Pulsatillae, cortex Phellodendri, radix et rhizoma Rhei, herba Patriniae, herba et Gemma Agrimoniae, charred radix Sangusorbae, radix aucklandiae preparata, rhizoma Bletillae, Notoginseng radix, and Glycyrrhrizae radix in water, and adding sanguis Draxonis.
5. The preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis according to claim 4, wherein the preparation method comprises the following steps: in each decoction, the weight of the added water is 5-20 times of the total weight of the traditional Chinese medicinal materials; the decocting times are 1-3 times, and the decocting time is 1-3 hours each time.
6. The preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis according to claim 4 or 5, characterized in that: adding water for decoction, and concentrating the decoction until the relative density is 1.05-1.15 to obtain a concentrated solution.
7. The preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis according to claim 6, wherein the preparation method comprises the following steps: after water is added for decoction, the decoction is concentrated to the relative density of 1.05-1.15, ethanol is added until the ethanol content of the decoction reaches 60-90%, then the extraction is carried out, solid-liquid separation is carried out, the supernatant is taken, and the ethanol in the supernatant is recovered to the full extent to obtain the concentrated solution.
8. The preparation method of the compound traditional Chinese medicine composition for inhibiting the inflammatory progression of active ulcerative colitis according to claim 6, wherein the preparation method comprises the following steps: adding or not adding sucrose into the concentrated solution, sterilizing, and making into syrup or decoction; or adding dextrin and steviosin into the concentrated solution, and making into tablet, capsule or granule.
9. The use of the compound Chinese medicinal composition for inhibiting the inflammatory progression of active ulcerative colitis according to claim 1, 2 or 3, wherein the compound Chinese medicinal composition comprises the following components in percentage by weight: the compound traditional Chinese medicine composition is applied to the preparation of medicines for inhibiting active ulcerative colitis and medicines for inhibiting colon cancer liver metastasis or rectal cancer liver metastasis.
10. The use of the compound Chinese medicinal composition for inhibiting the inflammatory progression of active ulcerative colitis according to claim 1, 2 or 3, wherein the compound Chinese medicinal composition comprises the following components in percentage by weight: the compound traditional Chinese medicine composition and the mesalazine are used together to prepare the medicine for inhibiting the active ulcerative colitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010546659.2A CN111686202A (en) | 2020-06-16 | 2020-06-16 | Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010546659.2A CN111686202A (en) | 2020-06-16 | 2020-06-16 | Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111686202A true CN111686202A (en) | 2020-09-22 |
Family
ID=72481351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010546659.2A Pending CN111686202A (en) | 2020-06-16 | 2020-06-16 | Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111686202A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109718317A (en) * | 2019-03-05 | 2019-05-07 | 上海中医药大学附属曙光医院 | A kind of Chinese medicine composition for treating ulcerative colitis |
| CN112826858A (en) * | 2021-04-08 | 2021-05-25 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Traditional Chinese medicine composition for treating ulcerative colitis and traditional Chinese medicine preparation and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739990A (en) * | 2015-04-01 | 2015-07-01 | 江苏省中医院 | Compound combined medicine for treating ulcerative colitis and preparation method and application thereof |
| CN105250821A (en) * | 2015-11-27 | 2016-01-20 | 辽宁中医药大学 | Traditional Chinese medicine compound preparation for treating ulcerative colitis and preparation method thereof |
| CN107582649A (en) * | 2016-07-06 | 2018-01-16 | 上海中医药大学附属龙华医院 | Treat compound Chinese medicinal preparation of IBD and preparation method thereof |
-
2020
- 2020-06-16 CN CN202010546659.2A patent/CN111686202A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739990A (en) * | 2015-04-01 | 2015-07-01 | 江苏省中医院 | Compound combined medicine for treating ulcerative colitis and preparation method and application thereof |
| CN105250821A (en) * | 2015-11-27 | 2016-01-20 | 辽宁中医药大学 | Traditional Chinese medicine compound preparation for treating ulcerative colitis and preparation method thereof |
| CN107582649A (en) * | 2016-07-06 | 2018-01-16 | 上海中医药大学附属龙华医院 | Treat compound Chinese medicinal preparation of IBD and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王晓瑜等: "清肠汤对热盛血瘀型溃疡性结肠炎患者的疗效及对HGF/c-MET表达的影响", 《道客巴巴》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109718317A (en) * | 2019-03-05 | 2019-05-07 | 上海中医药大学附属曙光医院 | A kind of Chinese medicine composition for treating ulcerative colitis |
| CN109718317B (en) * | 2019-03-05 | 2023-12-12 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating ulcerative colitis |
| CN112826858A (en) * | 2021-04-08 | 2021-05-25 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Traditional Chinese medicine composition for treating ulcerative colitis and traditional Chinese medicine preparation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111686202A (en) | Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof | |
| CN102210818B (en) | Chinese medicine for treating gastrorrhagia | |
| CN101890062B (en) | Use of nardostachys chinensis batal and extract thereof in preparation of medicaments for treating gastric ulcer | |
| CN111700938A (en) | A Chinese medicinal composition for treating pancreatitis and pancreatic pseudocyst | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN113648302A (en) | Medicine for treating prostatitis or prostatic hyperplasia | |
| CN104784651B (en) | A kind of method for preparing the pharmaceutical preparation for treating gastric ulcer | |
| CN116370596B (en) | A Chinese medicinal composition for treating biliary tract diseases | |
| CN116327826B (en) | A Chinese medicinal composition with antiinflammatory, analgesic or uric acid reducing effects and its preparation | |
| CN116617296B (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method and application thereof | |
| CN117414351B (en) | Traditional Chinese medicine patch for treating spleen-kidney yang deficiency constipation and preparation method and application thereof | |
| CN101926955B (en) | Medicament for treating stomach illness | |
| CN108578549B (en) | Medicine for treating acne and application thereof | |
| CN101194940A (en) | Anti-inflammation medicament for treating toothache and preparation method thereof | |
| CN117771156A (en) | Traditional Chinese medicine enema prescription for treating left half-colon ulcerative colitis in active phase | |
| CN101732469A (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| Chen et al. | TCM Clinical Treatment Progress of Ulcerative Colitis | |
| CN101011512A (en) | Medicine for treating digestive tract tumour and its preparing process | |
| CN113908212A (en) | Traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs, preparation method and preparation thereof | |
| CN118252897A (en) | Traditional Chinese medicine composition and preparation method and application method thereof | |
| CN116392558A (en) | Traditional Chinese medicine composition for treating adenomatous polyp of large intestine and application thereof | |
| Gong et al. | Shouhui Tongbian Capsule in treatment of constipation: Treatment and mechanism development | |
| CN113750082A (en) | Medicine for treating prostatitis and prostatic hyperplasia and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200922 |